Modernize The Treatment

with PLATAGG-I

(Clopidogrel Bisulphate) 75mg

to let the life goes on.....

PLATAGG-I

(Clopidogrel Bisulphate) 75mg

Modernize The Treatment to let the life goes on.....

Brilliant Effects

Acute Coronary Syndrome + Angioplasty

Tremendous Reduction

- MI
- Stroke
- Vascular deaths

Outstanding Results

- MI
- Stroke
- Recognized peripheral arterial disease

Exceptional Benefits

- Fast onset of action
- Highly documented
- High safety profile
- Highly economical

Brief Prescribing Information

Composition: Each film coated tablets of Platagg-I contains Clopidogrel 75mg. Clopidogrel Bisulphate 97.87mg. Platagg-I (Clopidogrel Bisulphate) is ADP-induced platelet aggregation inhibitor. Chemically it is methyl (+) - (s) - (2-chlorophenyl) 6,7-dihydro thieno [3,2-C] pyridine-5 (4H)-acetate sulphate (1:1). The empirical formula of Clopidogrel bisulphate is C16 H 16 Cl NO_2 S. H_2 SO_4 **Clinical Pharmacology: Mechanism of Action:** Clopidogrel is a platelet aggregation inhibitor acts by direct inhibition of adenosine diphosphate (ADP) binding to it's receptor and of the subsequent ADP-mediated activation of the glycoprotein GP IIb / IIIa complex. **Pharmacodynamic:** Inhibition of platelet aggregation which is dose dependent, can be seen 2 hours after single oral dose of 75mg Platagg-I. Repeated doses of 75mg Platagg-I per day inhibits ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days. **Pharmacokinetics:** Platagg-I is extensively metabolized by the liver. The main circulating metabolite is the carboxylic acid derivative and it has no effect on platelet aggregation., It represents 85% of the circulating drug-related compounds in plasma. Clopidogrel is rapidly absorbed after oral administration of repeated doses of 75mg. Peak Plasma concentration i.e. 3mg/L of main circulation metabolite usually achieves approximately 1 hour after dosing 50% of the compound is excreted in urine and 46% in the faeces in 5 days after dosing. The elimination half life of the main circulating metabolite is 8 hours after single and repeated administration. **Indications:** 1. Platagg-I reduces atherosclerotic events •Myocardial Infarction •Stroke •Vascular death. 2. Platagg-I is indicated in patients with •Recent Myocardial Infarction •Recent Stroke •Recognized peripheral arterial disease. **Contraindications:** Hypersensitivity to the drug or any excipient. Active pathological bleeding (Peptic ulcer or Intracranial haemorrhage). **Precautions:** •Pregnancy Category "B" •Patients who may be at risk of bleeding conditions such as trauma, surgery or other pathological bleedings. •Platagg-I should be used with caution in hepatically impaired patients. In elective surgery Platagg-I should be stopped 7 days before surgery. **Dosage and Administration:** The recommended dose of Platagg-I is 75mg once daily with or without food. No dosage adjustment is required for elderly patients or patients with renal disease.

Adverse Reactions:

Allergic Reaction	:	Haemorrhage
Gastrointestinal system	:	Abdominal Pain, Diarrhoea and Nausea
Cardiovascular	:	Edema, Hypertension
Central Nervous System	:	Headache
Psychiatric disorder	:	Depression
Skin disorder	:	Skin Rashes

Presentation: Blister strip of 10 White film coated tablets of Platagg-I each containing Clopidogrel 75 mg as clopidogrel bisulphate.
Pack of 1 x 10's

Prescribing information available on request.

"Medicines For All"

ZAFA Pharmaceutical Laboratories (Private) Ltd.
L-1/B, Block 22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI - 75950 (PAKISTAN)
Email: zafaph@cyber.net.pk, Website: www.zafa.com.pk

ISO 9001:2000